Skip to main content
. 2018 Sep 26;9:1084. doi: 10.3389/fphar.2018.01084

Table 2.

Affinity, potency and efficacy values (in vitro studies).

[3H]CP-55,940 binding
[35S]GTPγS binding
cAMP accumulation
Ligand pKi Ki (nM) N pEC50 EC50 (nM) EMAX N pIC50 IC50 (nM) IMAX N
CP-55,940 9.07 ± 0.13a,† 0.92 3 8.03 ± 0.18a 11.0 64.0 ± 3.8a 3 7.85 ± 0.16a,b,c 16.3 86.7 ± 6.4a 3
9Δ-THC 8.10 ± 0.17a 9.6 4 8.05 ± 0.14a 12.5 39.0 ± 2.7b 7 7.35 ± 0.20a,c 68.8 91.1 ± 2.3a 6
AB-PINACA 8.75 ± 0.25a 4.0 7 8.06 ± 0.17a 12.8 71.9 ± 5.8a 10 8.65 ± 0.19b 3.9 72.0 ± 2.1b 6
4OH-AB-PINACA 6.82 ± 0.09b 159 3 6.09 ± 0.12b 952 92.6 ± 13.4a 5 6.89 ± 0.17c 141 87.0 ± 2.9a 3
5OH-AB-PINACA 6.35 ± 0.06b 452 3 5.55 ± 0.08c 2742 100 ± 16.8a 3

EMAX and IMAX values are presented as the percent (%) of basal activity in the presence of vehicle. a,b,cpKi, pEC50, and pIC50 values designated by different letters are significantly different from values within the same column; P < 0.05, one-way ANOVA, Tukey’s post hoc test. pKi and Ki values for CP-55,940 were obtained from that previously published in Ford et al. (2017a).